Pfizer to buy Anacor Pharma in $5.2 billion deal
The deal will give Pfizer access to Anacor's non-steroidal topical gel to treat eczema16-05-2016
Pfizer to buy Anacor Pharma in $5.2 billion deal
The deal will give Pfizer access to Anacor's non-steroidal topical gel to treat eczemaPiramal Enterprises buys four Pfizer brands for Rs110 crore
The acquired brands, Ferradol, Neko, Sloan's and Waterbury's Compound, have a collective market size of approximately Rs7,000 croreSale of Four Product to Piramal Enterprises Limited
Pfizer Ltd has informed BSE that the Company has entered into an agreement with Piramal Enterprises Limited for sale of its 4 products viz., Neko Soap, Sloans, Ferradol and Waterbury's Compound for a total consideration of Rs. 110 Crores, subject to adjustments for inventory on closing and transaction costs.In this regard, the Company has issued the Press note.Transcript of the tele conference call with the analysts
Pfizer Ltd has informed BSE about the transcript of the tele conference call with the analysts held on May 6, 2016, to discuss the Company's financial performance for the quarter and the financial year ended March 31, 2016.Pfizer Q4 net profit spikes 57% to Rs 67 crore
The company had posted net profit of Rs 42.7 crore for the same period in the previous fiscal, Pfizer said in a BSE filing.Results Press Release for March 31, 2016
Pfizer Ltd has informed BSE about : 1. Result Press Release for the period ended March 31, 2016Board recommends Dividend
Pfizer Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 06, 2016, inter alia, have recommended a dividend of Rs. 15.00 per Equity share of Rs. 10/- each (150%) for the financial year ended March 31, 2016. The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on July 20, 2016.Announces Q4 & FY16 Results (Standalone), Form A (Standalone) & Auditors Report (Standalone) for the period ended March 31, 2016
Pfizer Ltd has announced the following results for the quarter & year ended March 31, 2016:The Audited Standalone results for the Quarter ended March 31, 2016The Company has posted a net profit of Rs. 669.70 million for the quarter ended March 31, 2016 as compared to Rs. 426.80 million for the quarter ended March 31, 2015. Total Income has increased from Rs. 4818.70 million for the quarter ended March 31, 2015 to Rs. 5434.40 million for the quarter ended March 31, 2016....Teleconference call on May 06, 2016
Pfizer Ltd has informed BSE that a teleconference call has been scheduled with the analysts on May 06, 2016, at 4.30 p.m. to discuss the Company's financial performance for the quarter and the financial year ended March 31, 2016.